Peginterferon lambda-1a
Also known as: BMS-914143, IFN-λ1a, LAMBDA, Lambda IFN, PEG-IFN‑λ, Pegasys Lambda, Peginterferon lambda, RG7011
Source Peginterferon lambda-1a at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peginterferon lambda-1a (also called Lambda, Peg-IFN‑λ) is an investigational, pegylated type‑III interferon administered subcutaneously once weekly. It has been studied primarily for chronic viral hepatitis (HCV and HBV) and, more recently, for outpatient COVID‑19. By engaging a receptor complex that is largely confined to hepatocytes, it aims to provide antiviral activity with fewer systemic side‑effects than the older type‑I (alfa) interferons.
Mechanism of Action
Lambda is a type‑III interferon that signals through the heterodimeric IFN‑λ receptor (IFNLR1/IL‑10R2) which is expressed mainly on epithelial cells of the liver and other limited tissues. Binding activates the JAK‑STAT pathway, inducing interferon‑stimulated genes that inhibit viral replication in hepatocytes. Because the receptor is sparsely distributed outside the liver, Lambda produces antiviral effects with reduced extra‑hepatic immune activation compared with type‑I interferons.
What the Research Shows
Phase‑2b EMERGE trials in treatment‑naïve chronic HCV genotype 1‑4 patients showed higher early virologic response rates for Lambda (120‑240 µg) versus peg‑IFN‑α‑2a, with comparable sustained virologic response (SVR) and fewer hematologic toxicities. A phase‑3 study adding daclatasvir to Lambda + ribavirin achieved an 88.8 % SVR12 versus 70.5 % for the standard peg‑IFN‑α‑2a + telaprevir regimen, with a more favorable safety profile. In chronic HBV, a phase‑2b LIRA‑B trial demonstrated faster early declines in HBV‑DNA and qHBsAg with Lambda, but final HBeAg seroconversion rates were similar to peg‑IFN‑α‑2a and non‑inferiority was not met at week 24 post‑treatment. A small COVID‑19 outpatient trial found a single 180 µg dose did not shorten viral shedding or symptom duration, though mild liver enzyme elevations were more frequent. A retrospective analysis of the EMERGE HCV data identified early hyperbilirubinemia due to ribavirin‑induced hemolysis and later bilirubin rises linked to possible hepatic toxicity of Lambda.
Reported Benefits
Clinical data indicate that Lambda can achieve at least comparable, and in some regimens superior, antiviral efficacy for HCV while producing fewer flu‑like, musculoskeletal and hematologic adverse events than peg‑IFN‑α. Early reductions in HBV‑DNA and qHBsAg suggest potent antiviral activity in HBV infection. The limited receptor distribution appears to translate into a differentiated safety profile, with lower rates of cytopenias and systemic symptoms.
Limitations of the Evidence
Lambda has not demonstrated superiority for HBV HBeAg seroconversion and failed to meet predefined non‑inferiority criteria at week 24 post‑treatment. Liver enzyme and bilirubin elevations can be dose‑limiting, especially at higher doses. The COVID‑19 trial showed no clinical benefit. All evidence comes from controlled trials; the compound remains investigational and is not approved for any indication. Long‑term outcomes and real‑world safety are still unknown.
Safety Considerations
The most common safety signals are elevations in alanine aminotransferase, bilirubin (both direct and indirect) and occasional hyperbilirubinemia, which may arise from ribavirin‑induced hemolysis early in therapy or direct hepatic effects of Lambda later. Compared with peg‑IFN‑α, Lambda is associated with fewer grade 3‑4 neutropenia, anemia, thrombocytopenia, and fewer flu‑like or musculoskeletal complaints. Serious adverse events occurred at similar frequencies in trials, but clinicians should monitor liver function tests and bilirubin regularly.
How It Is Administered
Peginterferon lambda‑1a is given as a subcutaneous injection once weekly. Doses evaluated in trials range from 120 µg to 240 µg, often combined with ribavirin and, in some studies, a direct‑acting antiviral such as daclatasvir. Formulations are supplied as a pegylated protein solution for injection; no oral or inhaled forms have been reported.
Routes of Administration
Goals & Uses
- Chronic hepatitis C (HCV) treatmentAntiviral / HepatologyModerate
- Chronic hepatitis CAntiviralModerate
- Chronic hepatitis B (HBV) functional cureAntiviral / HepatologyModerate
- COVID-19 treatment (outpatient)Antiviral / Infectious DiseaseHigh
- Respiratory viral infections (influenza, RSV)Antiviral / RespiratoryLow
- Chronic hepatitis BAntiviral / HepatologyModerate
- Chronic hepatitis delta virus (HDV) treatmentAntiviral / HepatologyModerate
- COVID‑19Viral InfectionLow
Contraindications
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
- Hypersensitivity to interferons or PEGImmunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Decompensated liver diseaseHepatic ImpairmentHigh
- Severe psychiatric disorders (untreated)PsychiatricHigh
Adverse Effects
- Elevated liver enzymes (ALT/AST flares)HepaticUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Elevated transaminasesHepaticUncommon
- Flu‑like syndromeSystemicCommon
- NeutropeniaHematologicUncommonLow neutrophil count
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Depression / Mood changesPsychiatricUncommon
- FatigueGeneralCommonLow energy or tiredness
- Injection‑site reactionLocalCommon
Drug Interactions
- Immunosuppressants (e.g., azathioprine, cyclosporine)Moderate
- Myelosuppressive agents (e.g., chemotherapy)Moderate
- Immunosuppressants (e.g., cyclosporine)Low
- CYP450 substrates (narrow therapeutic index)Low
- RibavirinModerate
Population Constraints
- Pediatric patients (<18 years)AgeRelative
- Pediatric patients (<12 y)AgeRelative
- Elderly (>75 y)AgeRelative
- Elderly (≥65 years)GeriatricRelative
- BreastfeedingReproductiveRelative
- Renal impairment (severe)RenalRelative
Regulatory Status
- European UnionInvestigationalEMA has not granted marketing authorization.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalMHRA classifies as clinical trial material only.
Approved in Canada (2023) under the brand name Pegasys Lambda for COVID-19 outpatient treatment. Under regulatory review or investigational in other jurisdictions including the US. Has orphan drug designations for HDV in the US and EU. Not FDA-approved as of early 2024.
Evidence & Sources
- Journal ArticleModerateZwirtes R, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateChan HLY, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateAndersen H, et al.2013-01-01T00:00:00.000000Z
- Journal ArticleModerateFlisiak R, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateJagannathan P, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateMuir AJ, et al.2014-01-01T00:00:00.000000Z
Frequently Asked Questions
How does peginterferon lambda‑1a differ from the older pegylated interferon‑α drugs?
Lambda binds a receptor complex that is largely restricted to hepatocytes, whereas interferon‑α receptors are widespread. This limited distribution reduces systemic side‑effects such as flu‑like symptoms and blood‑cell suppression, while still triggering antiviral pathways in liver cells.
Is peginterferon lambda‑1a approved for treating hepatitis C or B?
No. All available data come from phase‑2b and phase‑3 clinical trials; the drug remains investigational and has not received regulatory approval for any indication.
What are the main safety concerns when using Lambda?
Elevations in liver enzymes and bilirubin are the primary dose‑limiting toxicities. Early hyperbilirubinemia can be related to ribavirin‑induced hemolysis, while later increases may reflect hepatic effects of Lambda. Monitoring liver function and bilirubin is recommended.
Can a single dose of Lambda treat COVID‑19 infection?
A randomized placebo‑controlled trial in outpatients with mild COVID‑19 found that a single 180 µg subcutaneous dose did not shorten viral shedding or symptom duration, although it was generally well‑tolerated.
How is the drug administered in the hepatitis trials?
It is injected subcutaneously once weekly, typically at 120‑240 µg, together with ribavirin and sometimes a direct‑acting antiviral. The dosing schedule mirrors that of pegylated interferon‑α regimens.
What is Peginterferon lambda-1a?
Peginterferon lambda-1a (also called Lambda, Peg-IFN‑λ) is an investigational, pegylated type‑III interferon administered subcutaneously once weekly. It has been studied primarily for chronic viral hepatitis (HCV and HBV) and, more recently, for outpatient COVID‑19. By engaging a receptor complex that is largely confined to hepatocytes, it aims to provide antiviral activity with fewer systemic side‑effects than the older type‑I (alfa) interferons.
What is Peginterferon lambda-1a used for?
Peginterferon lambda-1a is educationally associated with: Chronic hepatitis C (HCV) treatment, Chronic hepatitis C, Chronic hepatitis B (HBV) functional cure, COVID-19 treatment (outpatient), Respiratory viral infections (influenza, RSV), Chronic hepatitis B, Chronic hepatitis delta virus (HDV) treatment, COVID‑19. Educational only — not medical advice.
How is Peginterferon lambda-1a administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Peginterferon lambda-1a?
Reported adverse effects include: Elevated liver enzymes (ALT/AST flares), Injection site reactions, Headache, Elevated transaminases, Flu‑like syndrome, Neutropenia, Nausea, Depression / Mood changes, Fatigue, Injection‑site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peginterferon lambda-1a?
Recorded contraindications: Severe hepatic impairment (Child‑Pugh C), Hypersensitivity to interferons or PEG, Pregnancy, Autoimmune hepatitis, Decompensated liver disease, Severe psychiatric disorders (untreated). Consult a qualified clinician before use.